https://www.selleckchem.com/pr....oducts/solcitinib.ht
011). The 1-year OS of patients with an NLR of 3 at 4 weeks was also better than that of those with an NLR of ≥3 (95% versus 71%, P = 0.02. Although the baseline NLR was not associated with PFS or OS, an NLR of ≥3 at 4 weeks after the initiation of therapy might be a robust predictor of poor PFS and OS in mRCC patients undergoing sequential treatment with nivolumab. Although the baseline NLR was not associated with PFS or OS, an NLR of ≥3 at 4 weeks after the initiation of therapy might be a robust predictor of poor PFS and OS
Like
Comment
Share
